Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301570 | 0.94 | TP53 (0.45) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301487 | 0.94 | GPBAR1 (0.46) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301506 | 0.94 | GPBAR1 (0.46) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301466 | 0.93 | MAPT (0.49) | MAPTTP53SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31301593 | 0.93 | MAPT (0.52) | MAPTTP53SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31301501 | 0.92 | ACKR3 (0.41) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301461 | 0.91 | POLB (0.39) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301355 | 0.91 | ALDH1A1 (0.40) | MAPTTP53SMN1; SMN2POLBACKR3 | |
| SCHEMBL31301460 | 0.91 | MAPT (0.43) | MAPTTP53SMN1; SMN2POLBNOTUM | |
| SCHEMBL31301359 | 0.91 | MAPT (0.43) | MAPTTP53SMN1; SMN2POLBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | MAPT 4575/4885TP53 4222/4885SMN1; SMN2 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.